Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/8/2018
SIETES contiene 92466 citas

 
 
 1 a 20 de 22 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]
2.Tiene citas relacionadas
Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-9. [Ref.ID 91419]
3.Tiene citas relacionadas
Roep BO. New hope for immune intervention therapy in type 1 diabetes. Lancet 2011;378:376-8. [Ref.ID 91414]
4.Tiene citas relacionadas Cita con resumen
Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised doubleb-blind trial. Lancet 2011;378:319-27. [Ref.ID 91402]
5. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
6.Tiene citas relacionadas Cita con resumen
Authier FJ, Gherardi RK. Safety and immunogenicity of H5N1 vaccine. Lancet 2007;368:2209-10. [Ref.ID 78720]
8. Cita con resumen
Roberts C G, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803. [Ref.ID 69359]
9.Tiene citas relacionadas
McInnes GT. Olmesartan medoxomil: viewpoint. Drugs 2002;62:1356. [Ref.ID 62164]
10.Tiene citas relacionadas
Ogihara T. Olmesartan medoxomil: viewpoint. Drugs 2002;62:1355. [Ref.ID 62163]
11.Tiene citas relacionadas
Fliser D. Olmesartan medoxomil: viewpoint. Drugs 2002;62:1354-5. [Ref.ID 62162]
12.Tiene citas relacionadas
Stumpe KO. Olmesartan medoxomil: viewpoint. Drugs 2002;62:1354. [Ref.ID 62161]
13.Tiene citas relacionadas
Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-53. [Ref.ID 62160]
14.
Osti M, Basadonna O, Pedrini A, Muraro N, Di Giacomo MC, Francioni G, Rebustello G, Marciani M, Merola P, Marchiori A, Ometto G, Dalla Via A. La prescrizione dei farmaci antisecretivi in Medicina Generale tra nota CUF e prescrizione indotta. Un modello di studio collaborativo. Ricerca e Pratica 2000;16:214-30. [Ref.ID 54202]
15. Cita con resumen
Sonnenberg A. Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia. Pharmacoeconomics 2000;17:391-401. [Ref.ID 50171]
17.
Roos T C, Merk HF. Important drug interactions in dermatology. Drugs 2000;59:181-92. [Ref.ID 49528]
18. Cita con resumen
Hanna FWF, Lazarus JH, Scanlon MF. Controversial aspects of thyroid disease. BMJ 1999;319:894-9. [Ref.ID 47098]
19.
Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70. [Ref.ID 45173]
20.
Dal Negro R. Pharmacokinetic drug interactions with anti-ulcer drugs. Clin Pharmacokinet 1998;35:135-50. [Ref.ID 39683]
Seleccionar todas
 
 1 a 20 de 22 siguiente >>